Everolimus Versus Sunit inib Prospective Evaluation in
Metastatic Non–Clear Cel l Renal Cell Carcinoma (ESPN):
A Randomized Mul ticenter Phase 2 Trial
72
Primary endpoint:
PFS in first line
Hypothesis:
12 w sunitinib
Æ
20 w everolimus
Tannir NM, et al. Eur Urol 2016;69:866‐74
